Immix Biopharma, Inc. $IMMX Shares Purchased by Sei Investments Co.

Sei Investments Co. boosted its position in Immix Biopharma, Inc. (NASDAQ:IMMX) by 100.0% in the 1st quarter, Holdings Channel reports. The fund owned 147,140 shares of the company’s stock after purchasing an additional 73,570 shares during the period. Sei Investments Co.’s holdings in Immix Biopharma were worth $1,340,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of IMMX. LGT Fund Management Co Ltd. boosted its holdings in shares of Immix Biopharma by 233.3% during the first quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock worth $3,795,000 after purchasing an additional 291,594 shares during the last quarter. Private Advisor Group LLC increased its stake in Immix Biopharma by 9.5% in the first quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock valued at $316,000 after purchasing an additional 3,000 shares during the last quarter. Kera Capital Partners Inc. purchased a new position in Immix Biopharma during the fourth quarter worth about $68,000. Virtu Financial LLC purchased a new position in Immix Biopharma during the fourth quarter worth about $386,000. Finally, KVP Capital Advisors LP acquired a new stake in Immix Biopharma in the 4th quarter worth about $1,205,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Price Performance

Immix Biopharma stock opened at $11.49 on Wednesday. The company has a market cap of $625.17 million, a price-to-earnings ratio of -13.06 and a beta of 0.11. Immix Biopharma, Inc. has a 12 month low of $1.94 and a 12 month high of $12.14. The stock’s 50-day moving average is $9.46 and its 200-day moving average is $8.94.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Research analysts anticipate that Immix Biopharma, Inc. will post -0.69 EPS for the current year.

Wall Street Analyst Weigh In

IMMX has been the subject of a number of research analyst reports. Needham & Company LLC began coverage on shares of Immix Biopharma in a research note on Wednesday, July 22nd. They set a “buy” rating and a $21.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Bank of America began coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating and a $27.00 target price for the company. Lifesci Capital began coverage on shares of Immix Biopharma in a research note on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price target on the stock. Finally, Citigroup began coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immix Biopharma currently has an average rating of “Moderate Buy” and an average target price of $21.29.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.